ERBB2 and triple-negative breast carcinoma: Currently, chemotherapy remains the cornerstone of treatment for advanced breast cancer, especially HR-positive HER-2 negative advanced breast cancer with visceral crisis; HER-2 positive advanced breast cancer and triple negative breast cancer.